Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Investor Presentation (2026)
9 slides from Zealand Pharma A/s's investor presentation, 2026
Slide 1: Zealand Pharma represents a unique investment opportunity
Zealand Pharma represents a unique investment opportunity Learn more about Zealand Pharma in our Corporate Presentation: Investors - Zealand Pharma 1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: Zealand Pharma is on the cusp of transforming into a generational biotech
Zealand Pharma is on the cusp of transforming into a generational biotech Redefining the near-term future of weight management Leading obesity programs backed by strong partners Building the world’s most valuable metabolic health pipeline Strong financial muscle to bridge the path to profitability 2
Slide 4: Redefining the near-term future of weight management
Redefining the near-term future of weight management Petrelintidea Petrelintide/CT-388a Survodutideb amylin + GLP-1/GIP fixed-dose glucagon/GLP-1 receptor dual agonist amylin analog combination Phase 3 program (obesity) reading out in 2026 Phase 3 trials (obesity) expected to Phase 2 initiation (obe
Slide 5: Leading obesity programs backed by strong partners (petrelintide)
Leading obesity programs backed by strong partners (petrelintide) Transformational partnership with Roche • Potential foundational, first choice treatment option setting a new standard for what to expect from a weight loss journey • Phase 2 ZUPREME-1 trial: Double-digit weight reduction with placebo
Slide 6: Leading obesity programs backed by strong partners (survodutide)
Leading obesity programs backed by strong partners (survodutide) Boehringer Ingelheim positioned as next obesity market entrant Boehringer Ingelheim “See Obesity, Think Liver” ➢ Global footprint with ~54,500 employees in 130 markets 1 ➢ Global leader in CVRM, including world’s best-selling SGLT-2 in
Slide 7: Building the world's most valuable metabolic health pipeline
Building the world’s most valuable metabolic health pipeline METABOLIC FRONTIER 2030 ACCELERATE 5 launches in 5 years Progress pre-clinical programs at speed PARTNER +10 clinical programs Evolve and fuel our platform Industry-leading cycle EXPAND times from idea to clinic Establish Boston site to st
Slide 8: Strong financial muscle to bridge the path to profitability
Strong financial muscle to bridge the path to profitability ILLUSTRATIVE Robust capital position more than sufficient to deliver on key strategic priorities Short- to mid-term topline drivers 13x 15,109 2026 • USD 125 million - anniversary payment (Roche) Cash position (DKK million)a increase vs. 20
Slide 9: 2026: Transformational milestones shaping long-term value creation
2026: Transformational milestones shaping long-term value creation NON-EXHAUSTIVE H1 2026 H2 2026 Petrelintide/CT-388 Petrelintide Initiation of Phase 2 Topline results from Phase 2 ZUPREME-2 Survodutide Topline results from key trials in Phase 3 obesity program (SYNCHRONIZETM-1, -2, -MASLD, -CVOT)